Intranasal Pneumococcal Vaccine Developed
Researchers have created a new vaccine candidate using modified bacteria to deliver protective pneumococcal antigens.
Updated on Oct. 14, 2026 in Asthma
Live Poll
Do you trust that emerging vaccine research will lead to more effective long-term disease protection?
Scientists developed an intranasal vaccine using Salmonella-derived outer membrane vesicles to combat Streptococcus pneumoniae. The experimental treatment showed broad, serotype-independent protection in preclinical animal models.
Why it matters
Current pneumococcal conjugate vaccines often fail to fully prevent colonization and transmission, leaving a significant gap in respiratory health protection. This new platform aims to address these limitations through improved mucosal and systemic immune responses.
The vaccine platform demonstrated sustained protection for 15 weeks in animal models post-vaccination. Researchers reported that the vaccine induced systemic and mucosal antibody responses across multiple pneumococcal strains.
The details
The vaccine utilizes SpyCatcher-SpyTag technology to covalently couple AliA and PnrA pneumococcal antigens to the surface of engineered Salmonella outer membrane vesicles. These vesicles serve as both a modular delivery system and an intrinsic adjuvant, triggering a strong IL-17 recall response.
Timeline
15 weeks of protection was maintained in animal subjects following the third dose.
Health Landscape
This research marks a significant departure from existing standards by shifting from systemic injection to intranasal delivery to target colonization more effectively. It addresses a long-standing challenge in vaccine science regarding the efficacy of traditional pneumococcal conjugate vaccines.
While the vaccine is currently limited to preclinical laboratory research, this platform could eventually offer a more effective method for preventing pneumococcal transmission. Future human trials will be required to determine how this technology might alter standard immunization schedules.
The takeaway
This intranasal approach represents a pivot toward mucosal immunity to stop respiratory bacteria before they colonize the host. If successfully scaled, the platform could provide more durable and broader protection against various pneumococcal strains than current options.
Further reading
Learn more about the latest innovations in respiratory health research in our Asthma section.
More information
Read the detailed results in the peer-reviewed research article.
Live Poll
Do you trust that emerging vaccine research will lead to more effective long-term disease protection?
